Fine-needle aspiration biopsy (FNAB) samples from thyroid tumor tissues were analyzed for
the presence of the BRAFT1796A mutation by polymerase chain reaction (PCR)-restriction …

Abstract The BRAF T1799A mutation is a heterozygous point mutation and its reported
prevalence in papillary thyroid carcinoma (PTC) has varied from 29 to 83%, with an overall …

BRAF mutations have been detected in 30% to 80% of papillary thyroid carcinomas (PTC).
Several detection methods for BRAF mutation have been reported, but a direct comparison …

Background: Fine needle aspiration (FNA) is routinely used in the preoperative evaluation of
thyroid nodules, but subsequent patient management is often complicated by the inability to …

The activating point mutation of the BRAF gene, BRAFT1799A, is the most common and
specific genetic alteration in adult papillary thyroid carcinoma (PTC) and a possible marker …

Numerous biomolecular markers have been studied to improve the accuracy of fine needle
aspiration biopsy (FNAB) in the diagnostic and prognostic evaluation of thyroid tumors, but …

Background: Fine-needle aspiration biopsy (FNAB) is the primary means of distinguishing
benign from malignant and of guiding therapeutic intervention in thyroid nodules. However …

Objective The somatic point mutation in the BRAF gene, which results in a valine-to-
glutamate substitution at residue 600 (BRAFV600E), is an ideal hallmark of papillary thyroid …

BACKGROUND The identification of BRAF mutations in thyroid cancer has prognostic and
therapeutic implications. Although the gold standard for identifying BRAF mutations is …

Assessing BRAF mutation status in thyroid fine needle aspiration (FNA) cytology samples by
both immunohistochemistry (IHC) and molecular methods has been documented in recent …